SIRT5 and infection: These observations support the assumption that drugs targeting SIRT3 and SIRT5 should not have a deletary impact on host defenses, which would contrast with drugs targeting classical HDACs that strongly impaired innate immune defenses against infections in preclinical models and clinical settings (78–84).